342 results on '"Lukina, Elena"'
Search Results
52. ¿Cómo prevenir la demencia? Guía de hábitos saludables para reducir el riesgo de demencia
53. Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
54. Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data
55. Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials
56. STUDENT ATTITUDE TO ETHICAL CONSUMPTION AS NEW ECOLOGICAL PRACTICE
57. Comparison of Three Flow Cytometry Scales in the Primary Diagnostics of Myelodysplastic Syndromes
58. Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
59. Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
60. Effects of oral eliglustat on skeletal manifestations in patients with type 1 Gaucher disease: Results from four completed clinical trials after long-term treatment
61. Outcomes of 19 unplanned pregnancies in women participating in phase 2 or 3 eliglustat clinical trials and 18 pregnancies in the partners of men who participated in these trials
62. Glucosylfingosine (Lyso-GL1) may be the primary biomarker for screening Gaucher disease in Russian patients
63. Surface functionalization via PEO coating and RGD peptide for nanostructured titanium implants and their in vitro assessment
64. Sodium borohydride reduction of 4-aryl-N-trifluoroacetyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline ozonide
65. Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
66. Management goals and normalization concept for type 1 Gaucher disease : Results from a survey of expert physicians
67. Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials.
68. Iron Overload in Patients with Paroxysmal Nocturnal Hemoglobinuria
69. Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials
70. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
71. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial
72. Management goals and normalization concept for type 1 Gaucher disease: Results from a survey of expert physicians
73. Long-term treatment response based on severity of Gaucher disease type 1 at baseline after 8 years of treatment with oral eliglustat: Final efficacy and safety results from a phase 2 clinical trial in treatment-naïve adult patients
74. Long-term stability in randomized and non-randomized patients in the phase 3 randomized, double-blind EDGE trial of once- versus twice-daily dosing of eliglustat in patients with Gaucher disease type 1
75. Fretting corrosion of nitinol spinal rods in with titanium pedicle screws
76. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians
77. Long-term results of ENGAGE: a phase 3, randomized, double‑blind, placebo-controlled, multi‑center study investigating the efficacy and safety of eliglustat in adults with type 1 Gaucher disease
78. Maintenance of quality of life in adults with type 1 Gaucher disease previously stabilized on enzyme therapy who were switched to oral eliglustat: 4 year results of the ENCORE trial
79. Medical histories in Gaucher disease: a descriptive analysis from 852 patients in the Gaucher Outcome Survey (GOS)
80. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
81. Hyaluronic acid based hydroxamate and conjugates with biologically active amines: In vitro effect on matrix metalloproteinase-2
82. The Gaucher Disease Outcome Survey: Description of the population in an ongoing international observational disease registry
83. Therapeutic goals and normal clinical values achieved within 4years of initiating velaglucerase alfa in treatment-naïve patients with Gaucher disease in phase 3 studies
84. Four-year follow-up from the ENCORE trial: A randomized, controlled, non-inferiority study comparing eliglustat to imiglucerase in patients with Gaucher disease type 1 stabilized on enzyme replacement therapy
85. Consensus Conference: A reappraisal of Gaucher disease - diagnosis and disease management algorithms
86. Long-Term Hematologic Response to Eliglustat in Patients with Gaucher Disease Type 1: Results from a Phase 2 and Two Phase 3 Trials
87. One-Pot Synthesis of Novel Cyclopentene-Fused Octahydropyridoquinolines and Octahydrophenanthrolines
88. Markers of bone turnover in patients with type 1 Gaucher disease receiving long-term velaglucerase alfa enzyme replacement therapy
89. ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results
90. Analysis of Retrieved Growth Guidance Sliding LSZ-4D Devices for Early Onset Scoliosis and Investigation of the Use of Nitinol Rods for This System
91. Long-Term Hematologic Response to Oral Eliglustat in Treatment-Naive Patients with Gaucher Disease Type 1: Final Results from a Phase 2 and the Phase 3 Engage Trials
92. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study
93. Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results
94. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment
95. Paper #1: Content of Metal Ions in the Blood and Tissues After Implantation of Titanium Growth-Guidance Sliding LSZ-4D Device for Early-Onset Scoliosis Treatment
96. Synthesis of 4-Aryl-8-fluoro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolines and Their Ozonides
97. ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals
98. Engage: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study To Investigate The Efficacy and Safety Of Eliglustat In Adults With Gaucher Disease Type 1: 9 Month Results
99. Partially oxidized potato starches from bromide-free TEMPO-mediated reaction: characterization of monosaccharide composition
100. Biomarker responses to eliglustat, an investigational oral substrate reduction therapy (SRT) for Gaucher disease type 1 (GD1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.